Growth Peptide Comparison
Overview
A side-by-side comparison of the six growth-factor and signalling compounds in this database — MK-677 (a non-peptide ghrelin mimetic), the peptide secretagogues Ipamorelin, GHRP-2 and GHRP-6, and the GHRH-receptor agonists CJC-1295 and Sermorelin. They split into two families — ghrelin-receptor (GHSR) agonists and GHRH-receptor agonists — which is the key to choosing between them.
Overview
| Feature | MK-677 | Ipamorelin | GHRP-2 | GHRP-6 | CJC-1295 | Sermorelin |
|---|---|---|---|---|---|---|
| Class | Non-peptide GHSR | Peptide GHSR | Peptide GHSR | Peptide GHSR | GHRH analogue (DAC) | GHRH(1–29) |
| Route | Oral | SC | SC | SC | SC | SC / IV |
| Half-life | ≈ 24 h | ≈ 2 h | ≈ 30 min | ≈ 30 min | ≈ 6–8 d | ≈ 12 min |
| Receptor | GHSR-1a | GHSR-1a | GHSR-1a | GHSR-1a | GHRH-R | GHRH-R |
Chemical Comparison
Chemistry below uses corrected/published values.
| Property | MK-677 | Ipamorelin | GHRP-2 | GHRP-6 | CJC-1295 | Sermorelin |
|---|---|---|---|---|---|---|
| CAS | 159634-47-0 | 170851-70-4 | 158861-67-7 | 87616-84-0 | 863288-34-8 | 86168-78-7 |
| Molecular weight | 528.7 | 711.9 | ≈ 817.9 | 873.0 | ≈ 3647 (DAC) | ≈ 3357.9 |
| Length | Non-peptide | 5 aa | 6 aa | 6 aa | 29–30 aa | 29 aa |
| Formula | C₂₇H₃₆N₄O₅S | C₃₈H₄₉N₉O₅ | C₄₅H₅₅N₉O₆ | C₄₆H₅₆N₁₂O₆ | (GHRH + DAC) | C₁₄₉H₂₄₆N₄₄O₄₂S |
Mechanism Comparison
Relative pharmacology (qualitative — established profiles, not fabricated figures):
| Property | MK-677 | Ipamorelin | GHRP-2 | GHRP-6 | CJC-1295 | Sermorelin |
|---|---|---|---|---|---|---|
| Receptor | GHSR-1a | GHSR-1a | GHSR-1a | GHSR-1a | GHRH-R | GHRH-R |
| Second messenger | Ca²⁺ / IP₃ | Ca²⁺ / IP₃ | Ca²⁺ / IP₃ | Ca²⁺ / IP₃ | cAMP / PKA | cAMP / PKA |
| GH release | Strong | Strong | Very strong | Strong | Strong (sustained) | Moderate |
| Prolactin | Minimal | Minimal | Mild | Significant | None | None |
| Appetite | Strong | Minimal | Moderate | Strong | None | None |
| Oral activity | Yes | No | Limited | Limited | No | No |
Pharmacological Comparison
| Parameter | MK-677 | Ipamorelin | GHRP-2 | GHRP-6 | CJC-1295 | Sermorelin |
|---|---|---|---|---|---|---|
| Half-life | ≈ 24 h | ≈ 2 h | ≈ 30 min | ≈ 30 min | ≈ 6–8 d | ≈ 12 min |
| Bioavailability | > 60% (oral) | 80–90% (SC) | 70–80% (SC) | 70–80% (SC) | 70–80% (SC) | 60–70% (SC) |
| Dosing frequency | Daily | 2–3× / day | 2–3× / day | 2–3× / day | Every 5–8 d | Daily |
| Metabolism | Hepatic (CYP3A4) | Proteolytic | Proteolytic | Proteolytic | Proteolytic | Proteolytic |
Safety Comparison
Published research observations; all are for research use only, not for human or veterinary use.
| Category | MK-677 | Ipamorelin | GHRP-2 | GHRP-6 | CJC-1295 | Sermorelin |
|---|---|---|---|---|---|---|
| Appetite increase | Strong | Minimal | Moderate | Strong | None | None |
| Prolactin | None | Minimal | Mild | Significant | None | None |
| Glucose impact | Transient rise | Minimal | Minimal | Minimal | Minimal | None |
| Route | Oral | SC | SC | SC | SC | SC |
Selection Considerations
Choose MK-677 when
Oral dosing and long, once-daily GH-axis modulation are wanted (note: small molecule, not a peptide).
Choose Ipamorelin when
A clean, selective GH pulse with minimal prolactin/cortisol/appetite is the goal.
Choose GHRP-2 when
Maximum GHSR potency / a strong GH pulse is the priority.
Choose GHRP-6 when
The first-generation benchmark, or ghrelin-appetite signalling, is being studied.
Choose CJC-1295 when
Sustained, multi-day GHRH-receptor activation is wanted (DAC form).
Choose Sermorelin when
A short-acting, physiological GHRH probe of the pituitary is needed.
GHRH + GHSR Rationale
A recurring research theme is pairing a GHRH-receptor agonist (CJC-1295 or Sermorelin) with a ghrelin-receptor agonist (a GHRP or Ipamorelin), because the two receptor systems act through different second messengers (cAMP vs Ca²⁺/IP₃) and are studied for complementary effects on GH release.
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Selected References
- Bowers CY. Growth-hormone-releasing peptide (GHRP) foundational literature.
- Raun K, et al. Ipamorelin, a selective GH secretagogue. European Journal of Endocrinology.
- Teichman SL, et al. Long-acting GHRH analogue CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
- Nass R, et al. Oral ghrelin mimetic MK-677 and body composition. Annals of Internal Medicine, 2008.
Quality & Supply
- All six compounds available research-grade, HPLC-characterized with a Certificate of Analysis per batch
- Peptides confirmed by LC-MS; MK-677 confirmed by NMR + MS
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need Growth Peptide Comparison — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
